Abgenix Inc., of Fremont, Calif., appointed Ward Wolff chief financial officer and senior vice president of finance.

Acusphere Inc., of Watertown, Mass., appointed Sandra Fenwick to its board.

Adherex Technologies Inc., of Research Triangle Park, N.C., appointed Rajesh Malik chief medical officer.

Androclus Therapeutics, of San Diego, formed a clinical advisory board composed of David Hafler, Robert Herndon and Antonio Uccelli.

Ariad Pharmaceuticals Inc., of Cambridge, Mass., appointed Peter Nelson to its board.

Avax Technologies Inc., of Philadelphia, appointed David Berd chief medical officer.

BioGenex Laboratories Inc., of San Ramon, Calif., appointed Dave Winkler chief financial officer and promoted Dave Sheldon to senior vice president and general manager.

Biophage Pharma, of Montreal, appointed Richard Sherman chairman and Bruce Schmidt chief business officer.

Biophan Technologies Inc., of Rochester, N.Y., appointed David Glocker to its scientific advisory board.

Cell Therapeutics Inc., of Seattle, appointed Richard Leigh executive vice president and general counsel.

Celsion Corp., of Columbia, Md., appointed Dudleigh Stone to its board, and as chairman of the audit committee and a member of the compensation committee.

Chronogen Inc., of Montreal, appointed Max Fehlmann president, CEO and board member.

Compugen Ltd., of Tel Aviv, Israel, appointed Noam Shani vice president of biology research and development.

Cortex Pharmaceuticals Inc., of Irvine, Calif., appointed Harry Mansbach chief medical officer and vice president of clinical development.

Diversa Corp., of San Diego, appointed Fernand Kaufmann to its board.

Genmab A/S, of Copenhagen, Denmark, appointed Matthew Dean vice president of sales and marketing.

Indevus Pharmaceuticals Inc., of Lexington, Mass., promoted Noah Beerman to executive vice president and chief business officer, and John Tucker to executive vice president of sales and marketing.

Pozen Inc., of Chapel Hill, N.C., appointed Marshall Reese executive vice president of product development.

Predix Pharmaceuticals Inc., of Woburn, Mass., appointed Stephen Donahue vice president of clinical and regulatory affairs.

Primagen Inc., of Atlanta, appointed Steve Owings president.

Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., appointed Alton Kremer vice president of clinical research.

S.R. One, of West Conshohocken, Pa., promoted Mark Strobeck to principal.

Sanaria Inc., of Rockville, Md., said its CEO and scientific officer, Stephen Hoffman, was elected a member of the Institute of Medicine of the National Academies of Sciences.

SciClone Pharmaceuticals Inc., of San Mateo, Calif., appointed Richard Hawkins to its board as a nonexecutive member.

Seattle Genetics Inc., of Bothell, Wash., appointed Iqbal Grewal vice president of preclinical therapeutics, and promoted Morris Rosenberg to senior vice president of development, and Paul Carter to vice president of antibody technologies.

Seattle Neuroscience Institute at Swedish Medical Center appointed Marc Mayberg executive director and David Newell co-director and medical director.

Southern Research Institute in Birmingham, Ala., appointed Colleen Jonsson director of the Emerging Pathogens research department.

Stressgen Biotechnologies Corp., of San Diego, appointed Gordon Barefoot to its board.

Sunesis Pharmaceuticals Inc., of South San Francisco, promoted Jennifer Troja to vice president of human resources.

Synta Pharmaceuticals Corp., of Lexington, Mass., appointed Ninad Deshpanday vice president of drug product development, Patricia McCall vice president of human resources, and Cynthia Clayton director of investor relations and corporate communications.

Synthetech Inc., of Albany, Ore., elected Noetzli to its board.

TargeGen Inc., of San Diego, appointed Charles Theuer vice president of clinical research and chief medical officer.

Tercica Inc., of South San Francisco, appointed David Mahoney to its board.

The Burnham Institute in La Jolla, Calif., appointed Nicole Dicks vice president of finance and chief financial officer, as well as treasurer.

TransMolecular Inc., of Birmingham, Ala., appointed John Ezcurra director of manufacturing.

VaxGen Inc., of Brisbane, Calif., appointed Kathrin Jansen senior vice president of research and development and chief scientific officer. It also appointed Myron Levine to its board.

Vion Pharmaceuticals Inc., of New Haven, Conn., promoted Ann Cahill to vice president of clinical development.

VistaGen Therapeutics Inc., of Burlingame, Calif., appointed Allen Cato, Jacqueline French and Lynn Kramer to its clinical advisory board.

Voyager Pharmaceutical Corp., of Raleigh, N.C., appointed Timothy Creech vice president of finance and chief accounting officer.

Zelos Therapeutics, of Waltham, Mass., appointed Lynn Barclay vice president of medical and clinical affairs.